## Development of HLA-G CAR-T cell therapy targeting HLA-G-positive solid tumors



| ONCOLOGY Preclinical     |  |
|--------------------------|--|
| Product Type             | Genetically modified autologous T cells  |
| Indication               | intractable solid tumors   |
| Target                   | HLA-G (human leukocyte antigen G)  |
| MoA(Mechanism of Action) | CAR-positive T cell therapy targeting HLA-G, which specifically expressed in the extravillous cytotrophoblast of the placenta  |
| Competitiveness          | <ol> <li>HLA-G is the optimal target (the best tumor specific antigen) in terms of reducing side effects of "on-target, off-tumor" because it is not expressed in normal cells except for placenta.</li> <li>Since HLA-G inhibits a large number of immune cells interaction with ILT2 and ILT4 expressed in immune cells, overexpression in the tumor is a powerful immune checkpoint.</li> <li>HLA-G CAR-T enables tumor direct killing and immune checkpoint inhibition at the same time; Since HLA-G expressing tumor cells is a powerful immune checkpoint, HLA-G CAR-T cells allows the restoration of the patient's immune response by eliminating HLA-G+ tumor cells.</li> </ol> |
| Development Stage        | Preclinical  |
| Route of Administration  | intravenous infusion   |

